|
1
|
National Kidney Foundation. K/DOQI
clinical practice guidelines for chronic kidney disease:
evaluation, classification, and stratification. Am J Kidney Dis.
39(2 Suppl 1): S1–S266. 2002.PubMed/NCBI
|
|
2
|
Vassalotti JA, Stevens LA and Levey AS:
Testing for chronic kidney disease: a position statement from the
National Kidney Foundation. Am J Kidney Dis. 50:169–180. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stevens LA and Levey AS: Current status
and future perspectives for CKD testing. Am J Kidney Dis. 53(3
Suppl 3): S17–S26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Levey AS and Coresh J: Chronic kidney
disease. Lancet. 379:165–180. 2012. View Article : Google Scholar
|
|
5
|
Hsu CY, Ordoñez JD, Chertow GM, Fan D,
McCulloch CE and Go AS: The risk of acute renal failure in patients
with chronic kidney disease. Kidney Int. 74:101–107. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
James MT, Hemmelgarn BR, Wiebe N, et al;
Alberta Kidney Disease Network. Glomerular filtration rate,
proteinuria, and the incidence and consequences of acute kidney
injury: a cohort study. Lancet. 376:2096–2103. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
James MT, Quan H, Tonelli M, et al;
Alberta Kidney Disease Network. CKD and risk of hospitalization and
death with pneumonia. Am J Kidney Dis. 54:24–32. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hailpern SM, Melamed ML, Cohen HW and
Hostetter TH: Moderate chronic kidney disease and cognitive
function in adults 20 to 59 years of age: Third National Health and
Nutrition Examination Survey (NHANES III). J Am Soc Nephrol.
18:2205–2213. 2007.
|
|
9
|
Miyamoto K, Ito M, Tatsumi S, Kuwahata M
and Segawa H: New aspect of renal phosphate reabsorption: the type
IIc sodium-dependent phosphate transporter. Am J Nephrol.
27:503–515. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hu P, Xuan Q, Hu B, Lu L, Wang J and Qin
YH: Fibroblast growth factor-23 helps explain the biphasic
cardiovascular effects of vitamin D in chronic kidney disease. Int
J Biol Sci. 8:663–671. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Slatopolsky E and Moe S: 50 years of
research and discovery in chronic kidney disease and mineral &
bone disorder: the central role of phosphate. Kidney Int Suppl.
S1–S2. 2011.PubMed/NCBI
|
|
12
|
Shigematsu T, Nakashima Y, Ohya M, et al:
The management of hyperphosphatemia by lanthanum carbonate in
chronic kidney disease patients. Int J Nephrol Renovasc Dis.
5:81–89. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gutierrez O, Isakova T, Rhee E, et al:
Fibroblast growth factor-23 mitigates hyperphosphatemia but
accentuates calcitriol deficiency in chronic kidney disease. J Am
Soc Nephrol. 16:2205–2215. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bia M, Adey DB, Bloom RD, Chan L, Kulkarni
S and Tomlanovich S: KDOQI US commentary on the 2009 KDIGO clinical
practice guideline for the care of kidney transplant recipients. Am
J Kidney Dis. 56:189–218. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Noordzij M, Korevaar JC, Boeschoten EW, et
al; Netherlands Cooperative Study on the Adequacy of Dialysis
(NECOSAD) Study Group. The Kidney Disease Outcomes Quality
Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in
CKD: association with mortality in dialysis patients. Am J Kidney
Dis. 46:925–932. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Daugirdas JT: Second generation
logarithmic estimates of single-pool variable volume Kt/V: an
analysis of error. J Am Soc Nephrol. 4:1205–1213. 1993.PubMed/NCBI
|
|
17
|
Perwad F, Zhang MY, Tenenhouse HS and
Portale AA: Fibroblast growth factor 23 impairs phosphorus and
vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin
D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal
Physiol. 293:F1577–F1583. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Goetz R, Nakada Y, Hu MC, et al: Isolated
C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting
FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci USA.
107:407–412. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen HC, Lim LM, Chang JM and Misra M:
Save life and improve quality: Report from the 5th Congress of
International Society for Hemodialysis. Hemodial Int. Jul
30–2013.(Epub ahead of print).
|
|
20
|
Urena Torres P, Friedlander G, de
Vernejoul MC, Silve C and Prié D: Bone mass does not correlate with
the serum fibroblast growth factor 23 in hemodialysis patients.
Kidney Int. 73:102–107. 2008.
|
|
21
|
Patrier L, Dupuy AM, Granger Vallée A, et
al: FGF-23 removal is improved by on-line high-efficiency
hemodiafiltration compared to conventional high flux hemodialysis.
J Nephrol. 26:342–349. 2013. View Article : Google Scholar : PubMed/NCBI
|
